Ready-to-Use Cardiac Organoids
Reliable efficacy validation and safety assessment are essential for advancing drug candidates with confidence. However, conventional preclinical models do not always provide the human-relevant insights needed to accurately predict cardiac risk before clinical development.
As the demand for more predictive safety evaluation continues to grow, 3D human-relevant models are becoming increasingly important. Compared with traditional 2D cultures and animal models, human iPSC-derived cardiac organoids better reflect the structural organization, multicellular complexity, and functional characteristics of human cardiac tissue.
As part of New Approach Methodologies (NAMs), cardiac organoid-based platforms provide a powerful tool to support drug-induced cardiotoxicity assessment, helping researchers generate more relevant data, improve predictive accuracy, and make better decisions earlier in drug development.
Product Introduction
Human cardiac organoids provide a physiologically relevant 3D platform for drug discovery and cardiac safety assessment. Yet in-house model establishment can be technically demanding, requiring specialized expertise, complex differentiation workflows, extended culture timelines, and rigorous process control.
ACROBiosystems' Ready-to-Use Cardiac Organoids are designed to overcome these barriers by providing an accessible, quality-controlled model with characterized functional performance, helping researchers accelerate assay development and generate high-value data with greater efficiency.
| Cat. No. | Product Description | Product Size |
|---|---|---|
| CIPO-HWL01 | Ready-to-use hiPSC-Derived Cardiac Organoids | 5 /20 /100 organoids |
| RIPO-HWM01 | hiPSC-Derived Cardiac Organoid Maintenance Kit | 80 / 220 mL |
*To support drug discovery and safety assessment, ACROBiosystems offers Microelectrode Array (MEA)-based functional testing service for evaluating electrophysiological activity and drug-induced functional responses. Additional readouts, including calcium imaging, immunostaining, ELISA, qPCR, and customized analyses, can also be provided based on project needs and feasibility.
Simple recovery after receipt saves time and resources
Contains key cardiac cell types, including cardiomyocytes, fibroblasts, endothelial cells, and smooth muscle cells
Provides reproducible functional readouts for cardiac safety evaluation
Controlled intra-batch variability, with consistent organoid size, beating behavior, and phenotypic characteristics
Operating Videos
Q&A
Q1: How are the products shipped?
Cardiac organoids are shipped under temperature-controlled conditions. The maintenance medium is provided in two packages: Box A with blue ice packs and Box B with dry ice.
Q2: How should the products be handled upon receipt?
Products are shipped from Day 25 of maturation. Recovery culture is recommended upon receipt. Days 25-35 represent the recommended usage window with stable function. Maintenance medium supports routine culture and medium exchange.
Q3: How is batch consistency ensured?
Batch consistency is ensured through standardized manufacturing and rigorous quality control, including size control, key functional assessments, and marker expression. Customers can access the corresponding Certificate of Analysis (COA) online using the batch number.
Q4: What applications and assays are supported?
The product supports multi-endpoint analysis, including beating/rhythm assessment, calcium transient analysis, ATP and LDH assays, apoptosis/stress marker detection, and sarcomere immunostaining (e.g., α-actinin and TNNT2). Suitable for mechanism studies, early-stage drug screening, and cardiac safety assessment.
- Background
- Product Introduction
- Resources
- Operating Videos
- Q&A
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved